Evaxion Biotech is committed to the discovery and development of vaccines against cancer and infectious diseases.
Since 2008, Evaxion has been redefining medicine and pioneering the discovery of antigens and neo-epitopes for developing ‘best in class’ immunotherapies at almost no cost.
We have constructed a robust product engine for the development of novel vaccines based on our two platforms, PIONEER and EDEN. Using state-of-the-art in silico tools, the platforms integrate big data, Artificial Intelligence and supercomputing to rapidly and affordably predict, rank and optimize epitopes and antigens that elicit a highly protective immune response.
Our office is situated in central Copenhagen and the heart of Medicon Valley, one of Europe’s largest international life-sciences cluster. With a primary focus on early vaccine development, we are building on a simple and scalable business model with manageable risk. Currently, Evaxion is collaborating with prominent human and veterinary vaccine companies, labs, and academic and governmental institutions in both Denmark and Boston, U.S., and has notably gained support from the Defense Advanced Research Project Agency (DARPA). Preclinical development is performed in collaboration with the University of Copenhagen and Southern University of Denmark.